Molecular Targeting Technologies (MTTI) will highlight advances on its EvaThera theranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) upcoming annual meeting.
The company's EvaThera platform includes EBTATE (lutetium-177-DOTA-EB-TATE) for neuroendocrine neoplasms, Hürthle cell thyroid, and nasopharyngeal cancers, and EBRGD (lutetium-177-DOTA-EB-RGD) for glioblastoma multiforme and non-small cell lung cancer. MTTI said a video featuring the EBTATE story will be released at the meeting.
In addition, two abstracts will be presented that feature EBTATE and the company's PET imaging radiotracer F-18 glucarate.
SNMMI's annual meeting is being held June 11-14 in Vancouver, BC.